Triple‐negative breast cancer (TNBC) represents a molecular subtype of BC (15%–20%) (Garrido‐Castro et al. 2019) that does not benefit from targeted therapies (anti‐HER2 and anti‐ER), like the other BC molecular subtypes, luminal A/B, or HER2+. Here, ERBB2 is linked to breast cancer.